Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.

Enliven Therapeutics, Inc.

Enliven Therapeutics is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help patients with cancer live not only longer, but better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall patient well-being. Enliven’s discovery process combines deep insights from clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. 

5AM Ventures

OrbiMed

Roche Venture Fund

Surveyor Capital

Boxer Capital

Janus Henderson Investors

Logos Capital

Cormorant Asset Management

Enliven Therapeutics

#DYK: Approximately 20% of people with CML switch therapy within the 1st year of treatment and up to 40% switch in the first 5 years of treatment. The majority of treatment switches occur early in the patient’s treatment course due to intolerance or lack and/or loss of molecular response. Join us on April 11th, to learn more about ELVN-001, our candidate for the treatment of CML: https://bit.ly/4cyFSP4

#DYK: Thanks to medical advancements, the number of patients living with #CML has more than doubled since the introduction of BCR-ABL TKIs, however, tolerability, safety, resistance and patient convenience concerns have become more prominent as patients can now expect to live on therapy for decades. Learn more: https://bit.ly/4afJ3cP 

We will be hosting a Virtual company event with KOLs on Thursday, 4/11, to discuss ELVN-001’s Phase 1a initial proof of concept data, the evolving treatment paradigm in #CML, and how ELVN-001 could fit into the CML landscape. Register here: https://bit.ly/4cyFSP4


#ICYMI: Yesterday we announced a $90M financing. We appreciate the support of our existing and new investors. This capital will help us continue to drive towards our goal of helping people with cancer to not only live longer, but live better. For more information, read the press release here: https://bit.ly/3TqPSkz 

Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress. Learn more here: https://bit.ly/3Ve4whJ

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	908K -	1.66M 82.60%	808K 51.27%	2.52M 212.00%	3.44M 36.37%	532K 84.53%
accumulated other comprehensive income loss		32K -				141K -
cash and cash equivalents	7.38M -	4.94M 33.13%	130.37M 2,541.11%	110.02M 15.60%	75.54M 31.35%	100.19M 32.65%
cash and short term investments	7.38M -	28.91M 291.59%	130.37M 350.98%	110.02M 15.60%	75.54M 31.35%	253.20M 235.21%
common stock	1K -	10K 900%	1K 90%	1K 0%	1K 0%	41K 4,000%
deferred revenue			429K -	2.70M 530.07%	5.51M 103.74%
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt
long term investments
net debt	-7.38M -	-4.94M 33.13%	-130.26M 2,538.98%	-109.86M 15.66%	-75.21M 31.54%	-99.86M 32.77%
net receivables
other assets
other current assets	323K -	1.72M 431.58%	222K 87.07%	646K 190.99%	2.22M 243.19%	12.95M 484.08%
other current liabilities	924K -	2.54M 174.89%	136K 94.65%	370K 172.06%	447K 20.81%	25.03M 5,498.88%
other liabilities
other non current assets		2.23M -		1.71M -	4.03M 136.30%	4.65M 15.51%
other non current liabilities	32.19M -	184K 99.43%	149.83M 81,328.80%	150.46M 0.42%	150.41M 0.04%	67K 99.96%
othertotal stockholders equity	4.97M -	83.63M 1,581.62%	157K 99.81%	2.31M 1,373.89%	6.04M 160.93%	128.31M 2,024.96%
preferred stock						271.87M -
property plant equipment net		442K -	416K 5.88%	954K 129.33%	1.52M 58.91%	1.06M 29.95%
retained earnings	-31.29M -	-54.75M 74.99%	-20.46M 62.63%	-45.20M 120.91%	-82.86M 83.32%	-154.45M 86.39%
short term debt			105K -	159K 51.43%	323K 103.14%	335K 3.72%
short term investments		23.97M -				153.01M -
tax assets
tax payables
total assets	7.71M -	33.30M 332.16%	131.00M 293.43%	113.33M 13.49%	83.30M 26.50%	271.87M 226.38%
total current assets	7.71M -	30.62M 297.46%	130.59M 326.42%	110.67M 15.25%	77.75M 29.74%	266.15M 242.30%
total current liabilities	1.83M -	4.20M 129.15%	1.48M 64.79%	5.75M 289.24%	9.71M 68.87%	25.89M 166.54%
total debt			105K -	159K 51.43%	323K 103.14%	335K 3.72%
total investments		23.97M -				153.01M -
total liabilities	34.02M -	4.38M 87.12%	151.31M 3,352.92%	156.22M 3.24%	160.12M 2.50%	25.96M 83.79%
total liabilities and stockholders equity	7.71M -	33.30M 332.16%	131.00M 293.43%	113.33M 13.49%	83.30M 26.50%	271.87M 226.38%
total non current assets		2.67M -	416K 84.44%	2.66M 539.18%	5.54M 108.54%	5.72M 3.08%
total non current liabilities	32.19M -	184K 99.43%	149.83M 81,328.80%	150.46M 0.42%	150.41M 0.04%	67K 99.96%
total stockholders equity	-26.32M -	28.92M 209.88%	-20.30M 170.22%	-42.89M 111.22%	-76.83M 79.13%	245.91M 420.09%

COM:ENLIVENTHERAPEUTICS

Enlivex Therapeutics Ltd.

Last Close

25.41

22/11 21:00

Market Cap

1.08B

Beta: -

Volume Today

254.16K

Avg: -

Preview